The New Process Validation Paradigm represents a move toward a more "proactive" pharmaceutical quality system. By treating validation as an ongoing journey rather than a destination, the industry ensures a more reliable supply of safe, effective medicines for patients.
It aligns with ICH Q8, Q9, and Q10 guidelines, facilitating smoother inspections and global compliance. Conclusion The New Process Validation Paradigm - ISPE Bost...
The new paradigm is structured into three distinct stages that move away from static documentation toward continuous learning: The New Process Validation Paradigm represents a move
The traditional approach to process validation, once viewed as a one-time "three-batch" hurdle, has undergone a fundamental shift toward a science-based, lifecycle approach. This new paradigm, championed by the ISPE and regulatory bodies like the FDA, emphasizes that quality cannot be tested into a product; it must be built in by design. The Lifecycle Framework Conclusion The new paradigm is structured into three
This stage replaces the rigid "three-batch" rule. Instead, the number of batches is determined by risk assessment and statistical confidence. It confirms that the process design is capable of reproducible commercial manufacturing.
